Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker.
Journal
Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693
Informations de publication
Date de publication:
12 Dec 2023
12 Dec 2023
Historique:
received:
24
03
2023
revised:
09
08
2023
accepted:
08
09
2023
pubmed:
12
9
2023
medline:
12
9
2023
entrez:
12
9
2023
Statut:
ppublish
Résumé
Improved biomarkers are needed for early cancer detection, risk stratification, treatment selection, and monitoring treatment response. Although proteins can be useful blood-based biomarkers, many have limited sensitivity or specificity for these applications. Long INterspersed Element-1 (LINE-1) open reading frame 1 protein (ORF1p) is a transposable element protein overexpressed in carcinomas and high-risk precursors during carcinogenesis with negligible expression in normal tissues, suggesting ORF1p could be a highly specific cancer biomarker. To explore ORF1p as a blood-based biomarker, we engineered ultrasensitive digital immunoassays that detect mid-attomolar (10-17 mol/L) ORF1p concentrations in plasma across multiple cancers with high specificity. Plasma ORF1p shows promise for early detection of ovarian cancer, improves diagnostic performance in a multianalyte panel, provides early therapeutic response monitoring in gastroesophageal cancers, and is prognostic for overall survival in gastroesophageal and colorectal cancers. Together, these observations nominate ORF1p as a multicancer biomarker with potential utility for disease detection and monitoring. The LINE-1 ORF1p transposon protein is pervasively expressed in many cancers and is a highly specific biomarker of multiple common, lethal carcinomas and their high-risk precursors in tissue and blood. Ultrasensitive ORF1p assays from as little as 25 μL plasma are novel, rapid, cost-effective tools in cancer detection and monitoring. See related commentary by Doucet and Cristofari, p. 2502. This article is featured in Selected Articles from This Issue, p. 2489.
Identifiants
pubmed: 37698949
pii: 731592
doi: 10.1158/2159-8290.CD-23-0313
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2532-2547Subventions
Organisme : NCI NIH HHS
ID : R01 CA240924
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA240243
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA276112
Pays : United States
Organisme : NCI NIH HHS
ID : U2C CA271871
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA228963
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA152990
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA233364
Pays : United States
Commentaires et corrections
Type : UpdateOf
Informations de copyright
©2023 The Authors; Published by the American Association for Cancer Research.